Information Provided By:
Fly News Breaks for January 14, 2020
Jan 14, 2020 | 06:28 EDT
JMP Securities analyst Donald Ellis raised his price target on Horizon Therapeutics to $47 and kept his Outperform rating after the company increased its peak sales estimates for KRYSTEXXA and Teprotumumab from over $750M to over $1B. The analyst cites the company's multiple immunomodulation studies for KRYSTEXXA showing improved responder rates and also points to the March 8th PDUFA date for Tepro where he "fully" expects approval, with additional plans for assessing further indications post-approval.
News For HZNP From the Last 2 Days
There are no results for your query HZNP